Collegium Pharmaceutical (COLL) Equity Average (2016 - 2025)
Historic Equity Average for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $253.5 million.
- Collegium Pharmaceutical's Equity Average rose 1245.44% to $253.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $253.5 million, marking a year-over-year increase of 1245.44%. This contributed to the annual value of $212.1 million for FY2024, which is 871.19% up from last year.
- Collegium Pharmaceutical's Equity Average amounted to $253.5 million in Q3 2025, which was up 1245.44% from $233.3 million recorded in Q2 2025.
- Over the past 5 years, Collegium Pharmaceutical's Equity Average peaked at $253.5 million during Q3 2025, and registered a low of $178.0 million during Q1 2021.
- Moreover, its 5-year median value for Equity Average was $208.8 million (2024), whereas its average is $211.4 million.
- Its Equity Average has fluctuated over the past 5 years, first surged by 5583.1% in 2021, then tumbled by 2169.03% in 2022.
- Over the past 5 years, Collegium Pharmaceutical's Equity Average (Quarter) stood at $227.0 million in 2021, then fell by 13.65% to $196.0 million in 2022, then fell by 4.52% to $187.2 million in 2023, then increased by 23.73% to $231.6 million in 2024, then grew by 9.48% to $253.5 million in 2025.
- Its last three reported values are $253.5 million in Q3 2025, $233.3 million for Q2 2025, and $231.6 million during Q1 2025.